

Financial news for EGRX dated on 2020-05-11: Eagle Pharmaceuticals: Q1 Earnings Insights

Financial news for EGRX dated on 2020-05-11: Eagle Pharmaceuticals Q1 EPS \$0.84 Beats \$0.57 Estimate, Sales \$46.020M Miss \$51.100M Estimate

Financial news for EGRX dated on 2020-05-10: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

Financial news for EGRX dated on 2020-05-04: Eagle Pharma Says it Plans to Request a Meeting with the FDA to Advance its EA-114 Program

Financial news for EGRX dated on 2020-04-28: UPDATE: Court In Eagle Pharma Case Upheld Asserted Patent Claims As Valid And Found That The Defendants' Proposed ANDA Products Would Infringe Claims

Financial news for EGRX dated on 2020-04-28: Court Issues Patent Litigation Decision For Eagle Pharmaceuticals, Inc. And Teva Pharmaceutical Industries Ltd. For BENDEKA (bendamustine hydrochloride injection)

Financial news for EGRX dated on 2020-04-20: 35 Stocks Moving in Monday's Pre-Market Session

Financial news for EGRX dated on 2020-04-16: The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant

Financial news for EGRX dated on 2020-04-16: Eagle Pharma Reports Lab Test Results Showing In Vitro Antiviral Activity Of RYANODEX Against Coronavirus

Financial news for EGRX dated on 2020-03-17: Eagle Pharmaceuticals Announces \$160M Buyback, Which Replaces Existing Buyback

Financial news for EGRX dated on 2020-03-13: Stocks That Hit 52-Week Lows On Friday

Financial news for EGRX dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for EGRX dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

Financial news for EGRX dated on 2020-03-06: Stocks That Hit 52-Week Lows On Friday

Financial news for EGRX dated on 2020-03-06: The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study

Financial news for EGRX dated on 2020-03-03: The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More

Financial news for EGRX dated on 2020-03-02: Cantor Fitzgerald Maintains Neutral on Eagle Pharmaceuticals, Lowers Price Target to \$46

Financial news for EGRX dated on 2020-03-02: Eagle Pharmaceuticals Q4 EPS \$0.49, Inline, Sales \$48.258M Miss \$49.07M Estimate

Financial news for EGRX dated on 2020-02-10: Eagle Pharmaceuticals Receives Final FDA Approval For PEMFEXY

Financial news for EGRX dated on 2020-01-13: Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimer's Disease in Collaboration With University of Pennsylvania

Financial news for EGRX dated on 2020-01-09: Eagle Pharma Reports Resubmission Of New Drug Application For RYANODEX For Exertional Heat Stroke

Financial news for EGRX dated on 2020-01-07: Tyme Technologies And Eagle Pharmaceuticals Announce Collaboration To Advance Oral SM-88 For Treatment Of Patients With Cancer; Tyme Entitled To Receive Total Of \$40M In The Form Of Upfront Payment And Milestones

Financial news for EGRX dated on 2019-12-16: Eagle Pharma Granted Orphan Drug Designation for RYANODEX for Treatment of Organophosphate Exposure by the FDA

Financial news for EGRX dated on 2019-12-13: Eagle Pharma Has Reached Settlement with Lilly related To PEMFEXY; All Claims Released, Allows For Initial Entry Of PEMFEXY Into Market On Feb. 1, 2022, Uncapped Entry Apr. 1, 2022

Financial news for EGRX dated on 2019-12-10: Eagle Pharmaceuticals Says Will Be

Submitting NDA For RYANODEX 'Shortly' Following Additional Communications With FDA

Financial news for EGRX dated on 2019-12-09: Eagle Pharmaceuticals Commences Dosing in Pilot Study for Novel Estrogen Receptor Antagonist Product Candidate

Financial news for EGRX dated on 2019-11-12: The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat

Financial news for EGRX dated on 2019-11-12: Eagle Pharmaceuticals Q3 Adj. EPS \$0.27 Misses \$0.57 Estimate, Sales \$41.147M Miss \$48.49M Estimate

Financial news for EGRX dated on 2019-11-04: Stocks That Hit 52-Week Highs On Monday

Financial news for EGRX dated on 2019-10-25: Stocks That Hit 52-Week Highs On Friday

Financial news for EGRX dated on 2019-10-16: The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch

Financial news for EGRX dated on 2019-10-07: Eagle Pharma Subsidiary Submits a New Drug Application for TREAKISYM

Financial news for EGRX dated on 2019-08-08: Eagle Pharmaceuticals Earlier Reported Q2 EPS \$0.84 Beats \$0.83 Estimate, Sales \$56.702M Beat \$53.59M Estimate

Financial news for EGRX dated on 2019-08-08: The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering

Financial news for EGRX dated on 2019-08-05: Eagle Pharma Announces Clinical Development Plan to Deliver Maximum Estrogen Receptor Inhibition in Patients with Estrogen Receptor (ER)-Positive Breast Cancer

Financial news for EGRX dated on 2019-05-07: The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex

Financial news for EGRX dated on 2019-05-07: Eagle Pharmaceuticals Q1 Adj. EPS \$1.01 Beats \$0.84 Estimate, Sales \$49.8M Beat \$48.15M Estimate

Financial news for EGRX dated on 2019-05-07: Eagle Pharmaceuticals Announces Results Of Study Conducted In Partnership US Military To Evaluate Neuroprotective Effects Of RYANODEX For Treatment Of Nerve Agent Exposure; Results Showed Statistically Significant Lower Incidence Of Brain Damage Compared

Financial news for EGRX dated on 2019-04-25: Jim Cramer Weighs In On Micron, Halliburton And More

Financial news for EGRX dated on 2019-04-23: Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'

Financial news for EGRX dated on 2019-04-22: Eagle Pharma Establishes a Billing Code for BELRAPZO 500mL Injection

Financial news for EGRX dated on 2019-04-15: Eagle Pharma Increases its Royalty Payment Split with Teva Pharma

Financial news for EGRX dated on 2019-02-28: The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems

Financial news for EGRX dated on 2019-02-28: Eagle Pharmaceuticals Q4 Adj. EPS \$1.20 Beats \$1.16 Estimate, Sales \$56.1M Beat \$54.17M Estimate

Financial news for EGRX dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for EGRX dated on 2018-12-20: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018

Financial news for EGRX dated on 2018-12-19: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018

Financial news for EGRX dated on 2018-12-14: Stocks Which Set New 52-Week Low Yesterday, Thurs., Dec. 13, 2018

Financial news for EGRX dated on 2018-12-14: The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch

Financial news for EGRX dated on 2018-12-10: Stocks Which Set New 52-Week Low The

Last Trading Session, Fri., Dec. 7, 2018

Financial news for EGRX dated on 2018-11-27: Eagle Pharmaceuticals Reports 'Positive' Results Of Pre-clinical Study Conducted To Evaluate Effects Of RYANODEX In Acute Radiation Syndrome

Financial news for EGRX dated on 2018-11-01: Stocks Which Set New 52-Week Low Yesterday, October 31st

Financial news for EGRX dated on 2018-11-01: Eagle Pharmaceuticals Q3 Adj. EPS \$1.18 Down From \$1.22 YoY, Sales \$51.337M Down From \$63.021M YoY

Financial news for EGRX dated on 2018-11-01: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Financial news for EGRX dated on 2018-10-31: 8 Biggest Price Target Changes For Wednesday

Financial news for EGRX dated on 2018-10-31: The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut

Financial news for EGRX dated on 2018-10-31: PiperJaffray Downgrades Eagle Pharmaceuticals to Neutral, Lowers Price Target to \$54

Financial news for EGRX dated on 2018-10-31: 64 Biggest Movers From Yesterday

Financial news for EGRX dated on 2018-10-30: 55 Stocks Moving In Tuesday's Mid-Day Session

Financial news for EGRX dated on 2018-10-30: Eagle Pharmaceuticals Sees Q3 Adj. EPS \$1.18 vs \$1.38 Est.

Financial news for EGRX dated on 2018-10-30: Eagle Pharmaceuticals Commences \$50M Buyback As Part Of New \$150M Share Repurchase Authorization

Financial news for EGRX dated on 2018-10-03: Eagle Pharmaceuticals Enters Into Agreement with USAMRICD To Evaluate Neuroprotective Effects Of RYANODEX Secondary To Nerve Agent Exposure

Financial news for EGRX dated on 2018-09-26: Eagle Pharma Names David Pernock COO

Financial news for EGRX dated on 2018-09-21: Cantor Fitzgerald Maintains Overweight on Eagle Pharmaceuticals, Lowers Price Target to \$80

Financial news for EGRX dated on 2018-08-31: 62 Biggest Movers From Yesterday

Financial news for EGRX dated on 2018-08-30: 45 Stocks Moving In Thursday's Mid-Day Session

Financial news for EGRX dated on 2018-08-30: Eagle Pharma Reports Completion Of Enrollment For Second Safety, Efficacy Study At Hajj To Evaluate RYANODEX For Exertional Heat Stroke

Financial news for EGRX dated on 2018-08-22: Eagle Pharmaceuticals Announces New Patent Issued for BENDEKA, Which Is Now Protected By 16 Patents Running From 2026-2033

Financial news for EGRX dated on 2018-08-07: The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmad's Antibiotic Faces FDA Panel

Financial news for EGRX dated on 2018-08-07: Eagle Pharmaceuticals Q2 EPS \$0.95 Beats \$0.80 Estimate, Sales \$59.3M Beat \$51.23M Estimate

Financial news for EGRX dated on 2018-07-23: Stocks Which Set New 52-Week Highs Friday

Financial news for EGRX dated on 2018-07-20: Stocks Which Set New 52-Week High Yesterday

Financial news for EGRX dated on 2018-07-20: Benzinga's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To Offer Shares, Intuitive Surgical's Strong Q2

Financial news for EGRX dated on 2018-07-12: Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial

Financial news for EGRX dated on 2018-07-09: Eagle Pharma's BENDEKA is Granted 7 Year Orphan Drug Exclusivity by the FDA

Financial news for EGRX dated on 2018-07-03: Eagle Pharma Reports New Patent Issued

For BENDEKA, Is Now Protected By 15 Patents Running From 2026-2033

Financial news for EGRX dated on 2018-06-11: Cantor Fitzgerald Initiates Coverage On 8 Pharma/Biotech Stocks After Hours: 7 With Overweight, 1 With Neutral Rating

Financial news for EGRX dated on 2018-06-11: Eagle Pharma Shares Down 1% Despite Earlier News Court Issued Decision In Favor Of Co. Related To Orphan Drug Exclusivity For BENDEKA; Mizuho Earlier Upgraded Stock From Underperform To Neutral

Financial news for EGRX dated on 2018-06-11: Benzinga Pro's 5 Stocks To Watch Today

Financial news for EGRX dated on 2018-06-11: Court Issues Decision In Favor Of Eagle Pharmaceuticals Granting Seven Year Orphan Drug Exclusivity For BENDEKA (bendamustine hydrochloride injection); FDA Will Be Unable To Approve Any Drug Applications Referencing BENDEKA Until ODE Expires In 2022

Financial news for EGRX dated on 2018-06-08: Eagle Pharmaceuticals Shares Up 7.9% After Hearing Word That Court Has Said Co. Should Receive Orphan Drug Designation For Bendeka

Financial news for EGRX dated on 2018-06-08: Eagle Pharma Shares Spike Following Word Court Has Said Should Receive Orphan Drug Designation For Bendeka

Financial news for EGRX dated on 2018-06-08: Eagle Pharma Shares Spike 6.4% Over Last Min., Now Up 7.3% For Session

Financial news for EGRX dated on 2018-05-16: Eagle Pharma Shares Up 2% Wed.; Co. Earlier Announced Granting Of Final FDA Approval For Bendamustine Hydrochloride Ready-To-Dilute Solution In 500ml Admixture; Co. Will Ship Product Immediately

Financial news for EGRX dated on 2018-05-10: Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results

Financial news for EGRX dated on 2018-05-10: Eagle Pharmaceuticals Q1 EPS \$0.53 Down From \$1.64 YoY, Sales \$46.6M Miss \$50.29M Estimate

Financial news for EGRX dated on 2018-05-09: Deutsche Bank Health Care Conference Concludes Today, Presenters Include: Cerus, ImmunoGen, and Eagle Pharmaceuticals

Financial news for EGRX dated on 2018-04-17: Endo Int'l Receives Notification Eagle Pharma Has Submitted ANDA to FDA Seeking Approval For A Generic Version of Vasostrict; Endo Says It Intends to 'Vigorously Protect Its Intellectual Property,' Including Potentially Filing Patent Infringement Lawsuit

Financial news for EGRX dated on 2018-04-16: Eagle Pharma Reports ANDA For Vasopressin Has Been Accepted For Filing By FDA

Financial news for EGRX dated on 2018-03-27: UPDATE: Eagle Pharma Says Patent Number 9,925,263 Will Expire Mar. 2036, Related To A Technology Which Allows For The Formulation Of Antibodies At High Concentration

Financial news for EGRX dated on 2018-03-27: Eagle Pharmaceuticals Announces New Patent for Eagle Biologics

Financial news for EGRX dated on 2018-02-27: 38 Biggest Movers From Yesterday

Financial news for EGRX dated on 2018-02-26: Eagle Pharmaceuticals Shares Down 8.5% Following Q4 Sales Miss But Inline Earnings

Financial news for EGRX dated on 2018-02-26: Eagle Pharma Reports Q4 Adj. EPS \$1.00 vs \$1.00 Est., Sales \$46.79M vs \$52.91M Est.

Financial news for EGRX dated on 2018-02-21: RBC Capital Global Healthcare Conference Begins Today, Presenters Include: Chemed, Revance, Eagle Pharma, Enanta, Gilead, TransEnterix, Immunogen, and Incyte

Financial news for EGRX dated on 2018-02-07: Eagle Pharma Granted a Patent for RYANODEX

Financial news for EGRX dated on 2017-12-07: Eagle Pharmaceuticals Commences Pivotal Study For Fulvestrant

Financial news for EGRX dated on 2017-11-29: Piper Jaffray Healthcare Conference Concludes Today, Presenters Include: Kadmon, Ignyta, Eagle Pharmaceuticals, Tandem Diabetes Care, DexCom, and Alnylam Pharmaceuticals

Financial news for EGRX dated on 2017-11-15: Jefferies 2107 London Healthcare Conference Begins Today, Presenters Include: Alkermes, Bristol-Myers, Immunogen, and Eagle Pharmaceuticals

Financial news for EGRX dated on 2017-11-08: Eagle Pharma Reports Q3 Adj. EPS \$1.22 vs \$0.80 Est., Sales \$63M vs \$50.9M Est.

Financial news for EGRX dated on 2017-10-27: Eagle Pharmaceuticals Receives Tentative FDA Approval for PEMFEXY

Financial news for EGRX dated on 2017-10-17: Eagle Pharma Issued a Patent for RYANODEX

Financial news for EGRX dated on 2017-08-09: Eagle Pharma Q2 Adj. EPS \$0.49 vs \$0.51 Est., Sales \$50.11M vs \$52.52M Est.

Financial news for EGRX dated on 2017-08-01: August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty

Financial news for EGRX dated on 2017-07-26: Eagle Pharmaceuticals Shares Down 20.69% At \$55.83/Share

Financial news for EGRX dated on 2017-07-26: Eagle Pharmaceuticals Receives Complete Response Letter from FDA on RYANODEX for Exertional Heat Stroke Application

Financial news for EGRX dated on 2017-07-25: UPDATE: Eagle Pharma Says 'NDA for RYANODEX was accepted for Priority Review, with review timelines within six months of the NDA submission. The PDUFA date was Sunday, July 23, 2017'

Financial news for EGRX dated on 2017-07-25: Eagle Pharma Offers Statement Related To RYANODEX Application PDUFA Date For Exertional Heat Stroke: Co. 'has not yet received correspondence from FDA'

Financial news for EGRX dated on 2017-07-21: REMINDER: Eagle Pharmaceuticals NDA PDUFA Date For Ryanodex Is Sunday, 7/23

Financial news for EGRX dated on 2017-07-05: Attention Biotech Investors: Keep Your Date With July PDUFA Action-Days

Financial news for EGRX dated on 2017-06-08: Eagle Pharmaceuticals Releases Investor Presentation

Financial news for EGRX dated on 2017-05-18: Bank Of America Health Care Conference Concludes Today; Presenters Include Boston Scientific, Humana, Universal Health, Chemed, Community Health, Eagle Pharma, Alnylam, Gilead, & Illumina

Financial news for EGRX dated on 2017-05-15: Eagle Pharma Announces Pete Meyers CFO

Financial news for EGRX dated on 2017-05-08: Eagle Pharma Q1 EPS \$1.42 vs \$1.42 Est, Sales \$76.8M vs \$70.4M Est

Financial news for EGRX dated on 2017-05-04: Deutsche Bank Health Care Conference Concludes Today, Presenters Include: Eagle Pharma, Foamix, Universal Health Services, NovoCure, & Bristol-Myers

Financial news for EGRX dated on 2017-03-27: Eagle Pharma Gets Priority FDA Review for Ryanodex NDA

Financial news for EGRX dated on 2017-03-21: Eagle Pharma Reports 3 New Patents Issued for Bendeka

Financial news for EGRX dated on 2017-03-17: Hearing Mizuho Out Negative On Eagle Pharmaceuticals, Cautious On External Heat Stroke Product Launch, Reiterates Underperform

Financial news for EGRX dated on 2017-03-01: Eagle Pharma Reports Q4 GAAP EPS \$3.75 May Not Compare to \$2.86 Est., Sales \$81.1M vs \$86.1M Est.

Financial news for EGRX dated on 2017-02-28: Eagle Pharmaceuticals' Novel Pemetrexed NDA Accepted for Filing by the FDA

Financial news for EGRX dated on 2017-02-21: Eagle Pharmaceuticals Announces New Patents Issued for Bendeka

Financial news for EGRX dated on 2017-01-23: Eagle Pharma Completes NDA for Ryanodex

Financial news for EGRX dated on 2017-01-09: The Market In 5 Minutes: Earnings Results, Conferences, Trump And More

Financial news for EGRX dated on 2017-01-09: Mizuho Downgrades Eagle Pharmaceuticals to Underperform, Lowers Target to \$64.00

Financial news for EGRX dated on 2017-01-03: Eagle Pharmaceuticals' Pemetrexed NDA Submitted to FDA for Review

Financial news for EGRX dated on 2016-12-19: Eagle Pharmaceuticals Names David Pernock Chief Commercial Officer

Financial news for EGRX dated on 2016-11-14: Wall Street's M&A Chatter From November 11-13

Financial news for EGRX dated on 2016-11-11: Eagle Pharma to Acquire Arsia Therapeutics for \$30M, Up to \$18M Additional May Be Paid for Milestones

Financial news for EGRX dated on 2016-11-11: Eagle Pharma Reports Initiation of Rolling Submission of NDA for Ryanodex in Exertional Heat Stroke

Financial news for EGRX dated on 2016-11-09: EAGLE PHARMACEUTICALS, INC.: SCHREIBER ALAIN (10%+) Sells 153,830 @ Avg Price: \$79.29 (Form4

Financial news for EGRX dated on 2016-11-09: Eagle Pharma Q3 EPS \$0.77 vs \$0.65 Est, Revenue \$37.8M vs \$41.1M Est

Financial news for EGRX dated on 2016-11-04: 10 Stocks That Rallied Three Days On No News

Financial news for EGRX dated on 2016-11-03: Mizuho Upgrades Eagle Pharmaceuticals, Inc. - Common Stock to Buy

Financial news for EGRX dated on 2016-11-02: William Blair Maintains Outperform on Eagle Pharmaceuticals, Inc. - Common Stock, Raises to \$97.00

Financial news for EGRX dated on 2016-11-02: Teva, Eagle Announce CMS Establishes Unique J-Code for BENDEKA(r) (Bendamustine Hydrochloride) Injection

Financial news for EGRX dated on 2016-10-31: Eagle Pharmaceuticals Announces Positive Initial Results of Animal Study Exploring Use of Ryanodex in MDMA Induced Hyperthermia Conducted at the National Institutes of Health

Financial news for EGRX dated on 2016-08-23: 15 Biggest Mid-Day Gainers For Tuesday

Financial news for EGRX dated on 2016-08-23: 20 Stocks Moving In Tuesday's Pre-Market Session

Financial news for EGRX dated on 2016-08-22: S&P Dow Jones Indices Says 'Chemical Financial Set to Join S&P MidCap 400; Supervalu, Shoe Carnival and Eagle

Financial news for EGRX dated on 2016-08-09: 18 Biggest Mid-Day Gainers For Tuesday

Financial news for EGRX dated on 2016-08-09: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for EGRX dated on 2016-08-09: Eagle Pharmaceuticals Reports Positive Outcome from FDA Meeting for Ryanodex for Exertional Heat Stroke NDA Submission; Says Reduced Future Ryanodex Royalty Obligations to Licensing Partner from 15% to 3% of Net Sales for Payment of \$15M in Cash

Financial news for EGRX dated on 2016-08-09: Eagle Pharma Q2 EPS \$0.84 vs \$0.71 est, Revenue \$40.9M vs \$40.8M est

Financial news for EGRX dated on 2016-07-05: Eagle Pharma Names Michael Graves Chair

Financial news for EGRX dated on 2016-06-27: Hudson Executive Capital LP Reports 6.1% Stake in Eagle Pharmaceuticals in 13D

Financial news for EGRX dated on 2016-06-20: Mid-Afternoon Market Update: Yelp Shares Gain Following Analyst Upgrade; Cypress Semiconductor Shares Drop

Financial news for EGRX dated on 2016-06-20: 6 Biggest Mid-Day Losers For Monday

Financial news for EGRX dated on 2016-06-20: Mid-Day Market Update: Crude Oil Rises 2.5%; Epizyme Shares Drop

Financial news for EGRX dated on 2016-06-20: Mid-Morning Market Update: Markets Open Higher; Icahn Enterprises Raises Offer For Federal Mogul

Financial news for EGRX dated on 2016-06-20: Mizuho Securities Downgrades Eagle Pharmaceuticals to Neutral

Financial news for EGRX dated on 2016-06-10: UPDATE: Teva Says US District Court of Delaware Ruled In Favor of Co. Related to Infringement Suit Against Hetero,

InnoPharma, Hospira, Sagent Pharma, Accord Healthshare

Financial news for EGRX dated on 2016-06-10: Teva Reports Favorable Court Ruling in TREANDA Infringement Case

Financial news for EGRX dated on 2016-06-10: 8 Biggest Mid-Day Gainers For Friday

Financial news for EGRX dated on 2016-06-10: Benzinga Receives Document Confirming Positive Ruling For Eagle Pharmaceuticals In Treanda Case

Financial news for EGRX dated on 2016-06-10: Eagle Pharma Resumes; Now \$53.77

Financial news for EGRX dated on 2016-06-10: Eagle Pharmaceuticals Up 27%, Shares Spiking

Financial news for EGRX dated on 2016-06-10: Eagle Pharmaceuticals Halted on CB at \$45

Financial news for EGRX dated on 2016-06-07: Watch These 5 Huge Call Purchases In Tuesday Trade

Financial news for EGRX dated on 2016-06-06: Option Alert: EGRX Jul16 40.0 Calls: 500 @ Above Ask! \$8.30: 500 traded vs 0 OI: \$41.88 Ref

Financial news for EGRX dated on 2016-05-26: Option Alert: EGRX Jun16 25.0 Puts Sweep: 1141 @ ASK \$0.30: 1207 traded vs 625 OI: \$46.54 Ref

Financial news for EGRX dated on 2016-05-25: Option Alert: EGRX Jun16 50.0 Calls: 500 @ ASK \$7.40: 1000 traded vs 938 OI: \$49.89 Ref

Financial news for EGRX dated on 2016-05-09: Mid-Day Market Update: TETRA Technologies Drops Following Weak Results; Krispy Kreme Shares Spike Higher

Financial news for EGRX dated on 2016-05-09: Mid-Morning Market Update: Markets Edge Higher; Tyson Foods Tops Q2 Estimates

Financial news for EGRX dated on 2016-05-09: Eagle Pharmaceuticals Reports Q1 EPS \$(0.06) vs. Est. \$(0.44), Rev. \$29.6M vs. Est. \$14.26M

Financial news for EGRX dated on 2016-04-20: Eagle Pharma Announces CMS Determines that Existing J-Code J9033 Adequately Describes BENDEKA Injection

Financial news for EGRX dated on 2016-03-31: Option Alert: EGRX Jun16 45.0 Calls Sweep: 760 @ ASK \$4.90: 760 traded vs 2241 OI: Earnings 5/10 \$39.99 Ref

Financial news for EGRX dated on 2016-03-28: Here's Why Eagle Pharmaceuticals Fell 7%

Financial news for EGRX dated on 2016-03-28: Eagle Pharmaceuticals and the National Institutes of Health (NIH/NIDA) Enter into Agreement to Explore Use of Ryanodex in MDMA (Ecstasy) and Methamphetamine Intoxication

Financial news for EGRX dated on 2016-03-28: Eagle Pharma's Request for 7 Year Orphan Exclusivity for Bendeka Denied by FDA

Financial news for EGRX dated on 2016-03-18: FDA Letter to Eagle Pharma Says More Information is Needed for KANGIO NDA

Financial news for EGRX dated on 2016-03-17: Option Alert: EGRX Jun16 50.0 Puts: 600 @ ASK \$7.50: 611 traded vs 77 OI: Earnings 5/10 \$54.16 Ref

Financial news for EGRX dated on 2016-02-25: Eagle Pharma Reports Q4 EPS \$0.07 vs \$(0.39) in the Same Qtr. Last Year, Sales \$18.2M vs \$20.8M Est.

Financial news for EGRX dated on 2016-02-23: Eagle Pharma Reports Received Sixth Patent for Bendamustine

Financial news for EGRX dated on 2016-02-02: Eagle Pharma Says Docetaxel Injection Commercially Available, Expects Annual Sales of \$75M

Financial news for EGRX dated on 2016-02-01: Eagle Pharma Announces FDA Granted Fast Track Designation to RYANODEX for Heat Strok

Financial news for EGRX dated on 2016-01-28: 8-K Filing From Eagle Pharmaceuticals Reports Teva Pharma Began Shipment Of BENDEKA, Coincides With Price Action Higher; However, Traders Believe Positive Note Circulating

Financial news for EGRX dated on 2016-01-28: Hearing Unconfirmed Market Chatter of Positive Note in Eagle Pharma

Financial news for EGRX dated on 2016-01-21: 13G Filing Shows Eagle Pharma Holder Park West Asset Mgmt LLC Holds 5.1% Stake

Financial news for EGRX dated on 2015-12-24: Eagle Pharma Reports FDA Approval of Docetaxel Injection

Financial news for EGRX dated on 2015-12-17: The Top 20 Wall Street Analysts Of 2015

Financial news for EGRX dated on 2015-12-17: Eagle Pharma Reports Successful Outcomes from Safety, Efficacy Study of RANODEX for Exertional Heat: 'Favorable Safety Data Shows No Significant Drug-Related Adverse Events'

Financial news for EGRX dated on 2015-12-14: The Five Best Biotech Analyst Calls Of 2015

Financial news for EGRX dated on 2015-12-09: Mizuho Securities Initiates Coverage on Eagle Pharmaceuticals at Buy, Announces \$112.00 PT

Financial news for EGRX dated on 2015-12-08: Mizuho Securities Initiates Coverage on Eagle Pharmaceuticals at Buy, Announces \$112.00 PT

Financial news for EGRX dated on 2015-12-08: Mid-Morning Market Update: Markets Tumble; AutoZone Profit Tops Estimates

Financial news for EGRX dated on 2015-12-08: Morning Market Gainers

Financial news for EGRX dated on 2015-12-08: Eagle Pharma Announces Receiving \$15M Milestone

Financial news for EGRX dated on 2015-12-08: Eagle Pharma. Achieves Milestone, Will Receive \$15M For BENDEKA Approval; Company Looks Forward To Teva's Successful Commercialization Of New Treatment Option

Financial news for EGRX dated on 2015-10-06: Eagle Pharma Announces Completion of Study For Ryanodex For Heat Stroke, Says Participants Showed no Drug Related Adverse Events

Financial news for EGRX dated on 2015-09-29: Eagle Pharmaceuticals Receives New Patent for Bendamustine Rapid Infusion Product

Financial news for EGRX dated on 2015-08-11: Eagle Pharma Reports Q2 Loss \$0.53 Vs Est \$0.57, Revs \$6M vs Est \$4.70M

Financial news for EGRX dated on 2015-07-29: Eagle Pharma Targets Hiked At Piper Jaffray On 'Room For Value Creation'

Financial news for EGRX dated on 2015-07-23: Eagle Pharmaceuticals Announces FDA Accepts RTU Bivalirudin NDA for Filing

Financial news for EGRX dated on 2015-06-22: Eagle Pharma Has 'Several Upcoming Catalysts' And Is A Buy, RBC Says

Financial news for EGRX dated on 2015-06-22: RBC Capital Initiates Coverage on Eagle Pharmaceuticals at Outperform, Announces \$97.00 PT

Financial news for EGRX dated on 2015-06-16: Cantor Fitzgerald Maintains Buy on Eagle Pharmaceuticals, Raises PT to \$95.00

Financial news for EGRX dated on 2015-05-20: Eagle Pharmaceuticals Submits NDA for Ready-to-Use Bivalirudin to FDA

Financial news for EGRX dated on 2015-05-19: New Patent Issued for Eagle Pharmaceuticals' Bendamustine Rapid Infusion Product

Financial news for EGRX dated on 2015-05-12: Eagle Pharma Q1 EPS \$1.31 vs \$1.47 est

Financial news for EGRX dated on 2015-05-12: Earnings Scheduled For May 12, 2015

Financial news for EGRX dated on 2015-04-14: Teva, Eagle Report NDA for Liquid Bendamustine Hydrochloride Rapid Infusion Product Has Been Accepted for Filing by FDA; PDUFA Date is December 2015

Financial news for EGRX dated on 2015-03-17: Benzinga's Volume Movers

Financial news for EGRX dated on 2015-03-17: Eagle Pharmaceuticals Announces 1.320M Shares Price At \$42.00/Share

Financial news for EGRX dated on 2015-03-17: Eagle Pharma Announces Offering Of 1.3M Shares At \$42.00/Share



Financial news for EGRX dated on 2015-03-16: Eagle Pharma Announces Commencement of \$50M Offering of Stock

Financial news for EGRX dated on 2015-02-23: Eagle Pharmaceuticals Spiking Over \$35

Financial news for EGRX dated on 2015-02-23: UPDATE: FDA Grants 7 Year Market Exclusivity To Eagle Pharma Ryanodex

Financial news for EGRX dated on 2015-02-23: FDA Grants Seven Years' Market Exclusivity to Eagle Pharmaceuticals' Ryanodex for the Treatment of Malignant Hyperthermia

Financial news for EGRX dated on 2015-02-19: Benzinga's Volume Movers

Financial news for EGRX dated on 2015-02-18: Benzinga's Volume Movers

Financial news for EGRX dated on 2015-02-17: Stocks Hitting 52-Week Highs

Financial news for EGRX dated on 2015-02-17: Morning Market Gainers

Financial news for EGRX dated on 2015-02-17: Teva, Eagle Pharmaceuticals Enter Exclusive License Agreement for EP-3102

Financial news for EGRX dated on 2015-02-02: Camber Capital Shows New 5.06% Passive Stake in Eagle Pharma

Financial news for EGRX dated on 2015-01-20: Eagle Pharmaceuticals Announces Change in Fiscal Year End

Financial news for EGRX dated on 2014-11-10: Eagle Pharmaceuticals Reports Positive Outcomes From Clinical Trial Of Bendamustine HCl Product Delivered Via Low-Volume, Rapidly Infused Admixture

Financial news for EGRX dated on 2014-10-15: Shares of Eagle Pharma Just Resumed Following Circuit Breaker, Shares Now Down 13.6%

Financial news for EGRX dated on 2014-09-17: Eagle Pharmaceuticals Announces That Teva Requests a Motion to Dismiss with Prejudice in Its Bendamustine Patent Infringement Lawsuit

Financial news for EGRX dated on 2014-08-11: Eagle Pharma Reports Q3 EPS of \$(0.21) Which May Not Compare \$(0.37) Est; Revenue of \$5.80M Which May Not Compare \$3.40M Est

Financial news for EGRX dated on 2014-08-11: Eagle Pharma Reports Q3 EPS of \$(0.21) vs \$(0.37) Est

Financial news for EGRX dated on 2014-08-11: Earnings Scheduled For August 11, 2014

Financial news for EGRX dated on 2014-07-23: Morning Market Movers

Financial news for EGRX dated on 2014-07-23: Benzinga's Top #PreMarket Gainers

Financial news for EGRX dated on 2014-07-23: US Stock Futures Rise Ahead Of Earnings

Financial news for EGRX dated on 2014-07-23: FDA Approves Eagle Pharmaceuticals' Ryanodex For The Treatment Of Malignant Hyperthermia

Financial news for EGRX dated on 2014-07-23: Eagle Pharma Announces FDA Approval For Malignant Hyperthermia With Ryanodex

Financial news for EGRX dated on 2014-07-08: Eagle Pharmaceuticals Announces Orphan Drug Designation

Financial news for EGRX dated on 2014-07-07: Eagle Pharma Shares Spiking Higher as Bloomberg Reporting Co. Has Received Orphan Drug Designation for Some Lymphomas

Financial news for EGRX dated on 2014-07-02: Eagle Pharmaceuticals Receives Tentative Approval For Patented, Ready-To-Dilute Bendamustine Hydrochloride Injection NDA

Financial news for EGRX dated on 2014-05-14: Eagle Pharma Reports Q2 EPS of \$(0.36) vs \$(0.26) Est; Revenue of \$3.22M vs \$3.20M Est

Financial news for EGRX dated on 2014-03-20: Morning Market Movers

Financial news for EGRX dated on 2014-03-20: UPDATE: Eagle Pharmaceuticals Shares Rise 8% on Announcement of NDA for Ryanodex Being Accepted by FDA with Priority Review

Financial news for EGRX dated on 2014-03-10: Top Trending Tickers On StockTwits For March 10

Financial news for EGRX dated on 2014-03-10: Benzinga's Top Initiations

Financial news for EGRX dated on 2014-03-10: William Blair Initiates Coverage on Eagle Pharma at Outperform

Financial news for EGRX dated on 2014-03-10: Cantor Fitzgerald Initiates Coverage on Eagle Pharma at Buy, Announces \$21.00 PT

Financial news for EGRX dated on 2014-03-10: Piper Jaffray Initiates Coverage on Eagle Pharma at Overweight, Announces \$22.00 PT

Financial news for EGRX dated on 2014-02-13: Three IPOs Hit Wall Street on February 12

Financial news for EGRX dated on 2014-02-12: Shares of Eagle Pharma Open at \$15.50/Share, Priced at \$15

Financial news for EGRX dated on 2014-02-12: Waiting on IPO Opens for Eagle Pharma at 10:25AM EST, Flexion Therapeutics at 10:50AM EST